| 摘要: |
| 目的观察联用瑞巴派特根除幽门螺杆菌的有效性和安全性。方法将120例Hp阳性的糜烂性胃炎、十二指肠炎及消化性溃疡患者随机分配到试验组和对照组,每组60例,对照组服用质子泵抑制剂雷贝拉唑钠+阿莫西林+克拉霉素;试验组服用质子泵抑制剂+阿莫西林+克拉霉素+瑞巴派特,服用14d以后仅服用雷贝拉唑4~6周,停药2周后复查C14呼气试验,评估幽门螺杆菌根除率和安全性。结果试验组(77.6%)根除效果优于对照组(66.7%),差异有统计学意义(P<0.05),两组不良反应差异无统计学意义(P>0.05)。结论标准三联方案基础上加用瑞巴派特根除幽门螺杆菌安全有效。 |
| 关键词: 幽门螺杆菌 瑞巴派特 三联疗法 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Observation of the Curative Effect of Rebamipide on the Eradication of Helicobacter Pylori |
|
Long Li;Huang Zhaoling;Cai Yumei
|
|
People’s Hospital of Jianwei County
|
| Abstract: |
| Objective To observe the efficacy and safety of Rebamipide in the eradication of helicobacter pylori.Methods120 cases of the Hp positive erosive gastritis,duodenitis and peptic ulcer patients were randomly assigned into the experimental group and the control group,within 60 cases each group.The control group were taken proton pump inhibitors rabeprazole azole sodium,amoxicillin and clarithromycin,while the experimental group were taken proton pump inhibitors,amoxicillin,clarithromycin and Rebamipide.After 14 days,all the patients were only taken rabeprazole for 4 ~ 6 weeks. After drug withdrawl for 2 weeks,The C14 breath test were done,and the helicobacter pylori eradication rate and safety were evaluated.Results The eradication effect of the experimental group( 77. 6 %) was better than the control group( 66. 7%),and the difference was statistically significant( P <0. 05).However,the difference between the two groups in adverse reactions was not statistically significant( P> 0. 05). Conclusion It’s safe and effective to use Rebamipide on the basis of the standard triple therapy in the eradication of helicobacter pylori. |
| Key words: rebamipide helicobacterpylori tripletherapy |
